Clinical trial registry record

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 19, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03844074
Last registry update
March 19, 2025
Status
Completed
Phase
Phase 3
Sponsor
Outlook Therapeutics, Inc.
Enrollment
61
Countries
Australia
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
Evidence population
Human clinical study registration
Participants
61
Population
ALL · 50 Years
Duration
2018-10-01 to 2020-08-13
Intervention
bevacizumab; ranibizumab
Comparator
ranibizumab
Outcomes measured
Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score — Baseline, 11 mont…; Mean change in the best corrected visual acuity over time — Baseline, monthly to 11 months; Proportion of participants who gain at least 10 letters in the best corrected visual acuity score — Baseline, 11 months; Proportion of participants who gain at least 5 letters in the best corrected visual acuity score — Baseline, 11 months; Proportion of participants who lose fewer than 15 letters in the best corrected visual acuity score — Baseline, 11 mont…; Proportion of participants with visual-acuity Snellen equivalent of 20/200 or worse — Baseline, 11 months; Percentage of participants with ocular adverse events, non-ocular adverse events, grade 3 and above laboratory abnormal…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON